Supplier Related Products Identification Chemical Properties Safety Data Raw materials And Preparation Products Material Safety Data Sheet(MSDS) Hazard Information Well-known Reagent Company Product Information
WebSite >  CAS DataBase List  > 486-66-8

486-66-8

Supplier Related Products Identification Chemical Properties Safety Data Raw materials And Preparation Products Material Safety Data Sheet(MSDS) Hazard Information Well-known Reagent Company Product Information

Product Image

Identification

Name
Daidzein
CAS
486-66-8
Synonyms
4',7-DIHYDROXYISOFLAVONE
4,7-DIHYDROXYISOFLAVONE
7,4'-DIHYDROXYISOFLAVONE
7-HYDROXY-3-(4-HYDROXYPHENYL)-4H-1-BENZOPYRAN-4-ONE
7-HYDROXY-3-(4-HYDROXY-PHENYL)-CHROMEN-4-ONE
7-HYDROXY-3-(4-HYDROXYPHENYL)CHROMONE
AKOS NCG1-0027
DAIDZEIN
ISOFLAVONE
4’,7-dihydroxy-isoflavon
7-Hydroxy-3-(4-hydroxyphenyl)-4-benzopyrone
7-hydroxy-3-(4-hydroxyphenyl)-4h-1-benzopyran-4-on
daidzeol
k251b
Daidsein
4,7-Dihydroxyisoflavone(Daidzein)
DAIDZEIN, 98+% FROM SOYBEAN
DAIDZEIN, (AMERICAN HERBAL PHARMACOPOEIA)
DAIDZEIN, 98% SYNTHETIC
DAIDZEIN, STANDARD FROM SOYBEAN 99+%(HPLC)
EINECS(EC#)
207-635-4
Molecular Formula
C15H10O4
MDL Number
MFCD00016954
Molecular Weight
254.24
MOL File
486-66-8.mol

Chemical Properties

Appearance
Off-White Crystalline Solid
Melting point 
315-323°C (dec.)
mp 
315-323°C (dec.)
Boiling point 
317.45°C (rough estimate)
density 
1.1629 (rough estimate)
refractive index 
1.4300 (estimate)
storage temp. 
2-8°C

solubility 
DMSO: 10 mg/mL

form 
Powder
pka
7.01±0.20(Predicted)
color 
White to off-white
Water Solubility 
insoluble
Usage
Inactive analog of Genistein (Cat. #G350000). Blocks the G1 phase of the cell cycle in Swiss 3T3 cells by inhibiting casein kinase II activity1. Daidzein has also been shown to inhibit the action of GABA on recombinant GABAA receptors2. uv max:25
Detection Methods
HPLC,NMR
Merck 
2801
BRN 
231523
CAS DataBase Reference
486-66-8(CAS DataBase Reference)
EPA Substance Registry System
486-66-8(EPA Substance)

Safety Data

Hazard Codes 
Xi
Risk Statements 
R36/38:Irritating to eyes and skin .
Safety Statements 
S24:Avoid contact with skin .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S37/39:Wear suitable gloves and eye/face protection .
WGK Germany 
3

RTECS 
DJ3100040

HazardClass 
IRRITANT
HS Code 
29329900

Raw materials And Preparation Products

Material Safety Data Sheet(MSDS)

Hazard Information

Description
Daidzein mainly comes from leguminous plants, the seeds of soybean (dadou), red clover grass, or all Pueraria roots. Its medicinal value was first recorded in Shen Nong Ben Cao Jing 2838 BC.?Daidzein, one of the main soy isoflavones, is also the main component of radix puerariae (Gegen) which is the dry root of kudzu leguminous plants. Radix puerariae can reduce fever, produce saliva, and relieve diarrhea. Its chemical composition is complicated, including puerarin, xyloside, soy flavonoids, soybean flavonoid glycosides, beta-sitosterol, daidzin, daidzein. The main effective components are puerarin and daidzein
Chemical Properties
Off-White Crystalline Solid
Physical properties
Appearance: pale-yellow prismatic crystal. Melting point: 315–323?°C. Solubility: soluble in ethanol and ether
History
Daidzein is a kind of isoflavone compound, which was first synthetized by researchers in China. It has been widely used in drugs, food supplements, and cosmetics. Because of two phenolic hydroxyl structures, Daidzein has poor water solubility, poor liposolubility, and strong first-pass effect, leading to the low bioavailability of oral absorption, which limits its widely clinical usage.
Ipriflavone is a kind of isoflavone modified from Daidzein, which has been used for the treatment of osteoporosis in Japan and some European countries. The effects of a series of amino alkoxy derivatives of ipriflavones on inhibiting the bone absorption were evaluated. The researchers found that 7-amino alkoxy derivative works best. When Daidzein was alkylated or acylated at 7-hydroxyl selectively, the stability was increased, and thus the proliferation of MCF-7 cell was inhibited.
Uses
Daidzein belongs to the group of isoflavones. Daidzein and other isoflavone compounds, such as genistein, are present in a number of plants and herbs. Soy isoflavones are a group of compounds found in and isolated from the soybean. Besides functioning as
Uses
phytoestrogen
Uses
Inactive analog of Genistein (Cat. #G350000). Blocks the G1 phase of the cell cycle in Swiss 3T3 cells by inhibiting casein kinase II activity1. Daidzein has also been shown to inhibit the action of GABA on recombinant GABAA receptors2. uv max:250 nm (log e 4.44)
Indications
Daidzein is mainly used for the treatment of hypertension, coronary heart disease, cerebral thrombosis, and vertigo and aids in the treatment of sudden deafness. It can also treat women with menopause syndrome.
Definition
ChEBI: A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone substituted by an additional hydroxy group at position 4'.
General Description
Daidzein is an endocrine-active estrogenic isoflavone. This phytoestrogen is capable to bind to estrogen to exert estrogenic effects in vivo. It can naturally be found in soybean seed and flour.

Biological Activity
Analog of the phytoestrogen genistein (5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one ). Blocks G 1 phase cell cycle progression and is an agonist at estrogen receptors.
Biochem/physiol Actions
Soy isoflavone daidzein protects against oxidative damage in liver cells induced by 7,12-dimethylbenz[a]anthracene (DMBA). Catalase and superoxide dismutase activity, down-regulated by DMBA, was restored by daidzein.
Pharmacology
Daidzein has many kinds of pharmacological effects, such as anticancer, cardiovascular protection, estrogen- and antiestrogen-like effects, antiosteoporosis, antioxidation, improving immunity, and affecting the endocrine system. More attention has been paid by domestic and international pharmaceutical and food industries. Daidzein has obviously antibacterial effect on Staphylococcus aureus and Escherichia coli. It can also increase the weight of immune organs in mice and has anti-arrhythmic effect. The chemical structure of daidzein is very similar to the endogenous estrogen, so the estrogen-like effect is used to treat menopausal syndrome and increase the levels of osteocalcin (BGP) and also the bone mineral deposits. The clinical efficacy is similar to estrogen replacement therapy (ERT). Daidzein doesn’t induce the high expression of estrogen. It has effects on the osteoblast to reduce the bone absorption of osteoclast, thus maintains the dynamic balance of osteoblast and osteoclast, finally reduces the risk of fracture. So it is safe for usage. Daidzein can also increase the bone mineral density (BMD) and bone mineral content (BMC) of the lumbar spine, the number of trabecular bone, and bone volume fraction, improve the bone microstructure, and thus prevent the reduction of femur biomechanics in glucocorticoid-induced osteoporosis in the rat.
Daidzein has an anti-hypoxia effect. The study showed that Daidzein could significantly prolong the survival time of mice in hypoxia tolerance test under normal pressure and after subcutaneous injection of isoproterenol, suggesting that Daidzein has the significant anti-hypoxia effects. Daidzein plays a protective role in myocardial hypertrophy induced by isoproterenol in rat probably by the antioxidative effects. Similarly, Daidzein may protect the ischemia-reperfusion injury in rats by increasing the antioxidative capacity. Daidzein can significantly inhibit the proliferation of two human breast cancer cells (MCF-7 and MDA-MB-231) in?vitro with the significant dose-dependent and time-dependent effects. Daidzein can markedly decrease the colony-forming ability, suggesting that Daidzein may have the effect of preventing and treating breast cancer.
It was found that Daidzein has the obviously preventive effect on chloroforminduced ventricular fibrillation in mice, therapeutic effect on aconitine-induced arrhythmia in rats, as well as protective effect on the adrenaline-induced arrhythmia in rabbit. Daidzein can significantly reduce the action potential amplitude of sciatic nerve in toad in?vitro. All of the above effects were obviously dose-dependent, suggesting Daidzein has the significant anti-arrhythmic effects
Clinical Use
Daidzein can expand the coronary artery, femoral artery, and cerebral artery, increase cerebral blood flow and limb blood circulation, reduce blood viscosity and vascular resistance, decrease myocardial oxygen consumption, improve heartfunction, increase the microcirculation and blood flow to the tip, lower the blood pressure, and adjust the heart rhythm. Daidzein can be used for the treatment of hypertension, coronary heart disease, angina pectoris, myocardial infarction, cerebral thrombosis, dizziness, and sudden deafness. It can also be used for women’s menopause syndrome.

Well-known Reagent Company Product Information

SupplierMore